Product Images Lubiprostone
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Lubiprostone NDC 43602-549 by Ascent Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
24 mcg - 24 mcg
8 mcg - 8 mcg
Structure - Structure
Table1 - Table 1
This text provides a table outlining the recommended dosage regimen for CIC and OIC IBS-C in adults with different levels of hepatic impairment based on Child-Pugh Class. It suggests specific dosage adjustments for moderate and severe impairment, as well as guidance on escalating doses if needed. The recommended dosages range from 8 to 24 meg twice daily, with adjustments made according to the patient's response and tolerance.*
Table 2 - Table 2
This text provides information about adverse reactions reported in clinical trials of adults with Chronic Idiopathic Constipation (CIC) who were treated with Lubiprostone capsules compared to a placebo. Adverse reactions listed include nausea, diarrhea, headache, abdominal pain, abdominal distension, flatulence, vomiting, loose stools, edema, abdominal discomfort, dizziness, chest discomfort/pain, dyspnea, dyspepsia, fatigue, and dry mouth. The table shows the percentage of patients experiencing each adverse reaction.*
Table 3 - Table 3
This is a table showing the adverse reactions reported in clinical trials of adults with opioid-induced constipation (OIC) who were treated with Lubiprostone capsules compared to a placebo. Adverse reactions such as nausea, diarrhea, abdominal pain, flatulence, abdominal distension, vomiting, headache, peripheral edema, and abdominal discomfort were evaluated. The percentages of these reactions in the treatment group (N=860) were compared to those in the placebo group (N=632). The table indicates that adverse reactions like diarrhea, nausea, and abdominal pain were more frequently reported in the Lubiprostone group compared to the placebo group.*
Table 4 - Table 4
Table 5 - Table 5
This table presents pharmacokinetic parameters of the metabolite M3 for subjects with normal or impaired liver function after being administered Lubiprostone Capsules. The Mean (SD) values for AUCo and Canax Change are provided for subjects with Normal liver function as well as those classified under Child-Pugh Class B and Class C. The table shows percentage changes compared to the Normal liver function group.*
Table 6 - Table 6
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
